Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 15;39(5):74.
doi: 10.1007/s12032-022-01675-2.

PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer

Sutapa Mahata  1 , Pranab K Sahoo  1 , Ranita Pal  1 , Sinjini Sarkar  1 , Tanuma Mistry  1 , Sushmita Ghosh  1 , Vilas D Nasare  2
Affiliations
Review

PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer

Sutapa Mahata et al. Med Oncol. .

Abstract

Triple-negative breast cancer lacks an expression of ER, PR, and Her-2, has a poor prognosis, and there are no target therapies available. Therapeutic options to treat TNBC are limited and urgently needed. Strong evidence indicates that molecular signaling pathways have a significant function to regulate biological mechanisms and their abnormal expression endows with the development of cancer. PIM kinase is overexpressed in various human cancers including TNBC which is regulated by various signaling pathways that are crucial for cancer cell proliferation and survival and also make PIM kinase as an attractive drug target. One of the targets of the STAT3 signaling pathway is PIM1 that plays a key role in tumor progression and transformation. In this review, we accumulate the current scenario of the PIM-STAT3 axis that provides insights into the PIM1 and STAT3 inhibitors which can be developed as potential co-inhibitors as prospective anticancer agents.

Keywords: PIM inhibitors; PIM1; STAT3; STAT3 inhibitors; Triple-negative breast cancer.

PubMed Disclaimer

References

    1. Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast. 2015;24(Suppl 2):S36-40. - PubMed
    1. Bayraktar S, Gluck S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2013;138(1):21–35. - PubMed
    1. Nath A, et al. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer. Med Oncol. 2021;39(1):14. - PubMed
    1. Cuypers HT, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37(1):141–50. - PubMed
    1. Braso-Maristany F, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016;22(11):1303–13. - PubMed - PMC

MeSH terms

LinkOut - more resources